Missing Components of Receptor Status Among Women With Invasive Breast Cancer.

ABSTRACT:

Importance

There are well-known differences in patient outcomes and effective therapeutic options across subtypes of breast cancer (BC), defined by the status of estrogen receptor, progesterone receptor, and erb-B2 receptor tyrosine kinase 2 (ERBB2 [formerly HER2]) expression, making testing for these receptors part of the routine workup for all patients with a diagnosis of invasive BC. Despite its importance, this information is missing in some BC cases.

Objective

To identify female patients with BC without record of testing for estrogen receptor, progesterone receptor, or ERBB2 status, defined as missing components of receptor status (MCRS).

Design, setting, and participants

This cross-sectional study used data from National Cancer Institute's Surveillance, Epidemio

SUBMITTER: Stephens JA 

PROVIDER: S-EPMC10450568 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature